InsidersTradesSigma
Follow the Climb Bio, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €791.4m. The latest transaction was reported on 30 June 2026 (Levée d'options). Among the most active insiders: Pimblett Emily. The full history is free.
Analysts rate Climb Bio, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$20.93.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
7 of 7 declarations
Climb Bio, Inc. is a company focused on developing innovative therapies for genetic diseases. It is listed on the XNAS market.